SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Big Pharma Preps to Spend Hundreds of Millions to Keep Drug Prices High
"PhRMA's decision to hike membership dues 50 percent will increase the trade group's considerable coffers to more than $300 million per year," Politico reports
Oct 25, 2016
Facing an increasingly outraged public, the leading Big Pharma lobby group is hiking its annual dues by more than 50 percent as it prepares to defend its pharmaceutical company members against lawmakers and voters who want to rein in out-of-control drug prices.
Politico reported Tuesday that "PhRMA hopes to improve its public image next year and stave off any legislative action" in the wake of recent public scandals like those over EpiPen and Valeant. "It plans to run TV ads emphasizing how new drugs could add years to patients' lives, as well as the years of complex research needed to develop a drug--in other words, a lot of money that must be recouped through high prices."
To do so, it needs some extra cash.
As such, "PhRMA's decision to hike membership dues 50 percent will increase the trade group's considerable coffers to more than $300 million per year," according to Politico, "a financial advantage it hasn't enjoyed since 2009, when drug makers came out largely unscathed in Obamacare negotiations."
Politico first reported on PhRMA's board voting to raise dues in August, but didn't know then by how much. "They are formidable under any scenario. They are formidable now," Hillary Clinton health policy adviser Chris Jennings said at the time. "The idea that they are going to bring in more resources, borders on petrifying."
But an angry public, led by progressive voices, is potentially just as formidable.
A recent poll found that more than three in four Americans believe that prescription drug prices are "unreasonable," with large majorities from both major political parties in favor of government steps to keep those prices down.
On Monday, STAT reported that "a coalition of 300 institutional investors has filed shareholder resolutions with 11 big U.S. drug makers to explain and justify all price increases and the risks these may pose to stockholders."
And just last week, Sen. Bernie Sanders (I-Vt.) penned an op-ed in favor of the California Drug Price Relief Act, also known as Proposition 61, which seeks to rein in prescription drug prices. Voting yes on Proposition 61, he wrote on Friday, would not only help "make medicine more affordable in California," but would also "send a signal to Washington that the whole nation's prescription drug policies need an overhaul."
Big Pharma has been ardently fighting that measure, as Politico reports--though polls suggest the ballot measure is still poised to win.
On Tuesday, Sanders tweeted in response to the Politico piece:
And he pushed back on the narrative that Big Pharma is likely to employ in its effort to clean up its image.
As the group Health GAP, which campaigns for HIV drug access worldwide, wrote Tuesday on Twitter: "PhRMA is filling a war chest & preparing for battle to keep drug prices high. We need to be prepared to fight back!"
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Deirdre Fulton
Deirdre Fulton is a former Common Dreams senior editor and staff writer. Previously she worked as an editor and writer for the Portland Phoenix and the Boston Phoenix, where she was honored by the New England Press Association and the Association of Alternative Newsweeklies. A Boston University graduate, Deirdre is a co-founder of the Maine-based Lorem Ipsum Theater Collective and the PortFringe theater festival. She writes young adult fiction in her spare time.
Facing an increasingly outraged public, the leading Big Pharma lobby group is hiking its annual dues by more than 50 percent as it prepares to defend its pharmaceutical company members against lawmakers and voters who want to rein in out-of-control drug prices.
Politico reported Tuesday that "PhRMA hopes to improve its public image next year and stave off any legislative action" in the wake of recent public scandals like those over EpiPen and Valeant. "It plans to run TV ads emphasizing how new drugs could add years to patients' lives, as well as the years of complex research needed to develop a drug--in other words, a lot of money that must be recouped through high prices."
To do so, it needs some extra cash.
As such, "PhRMA's decision to hike membership dues 50 percent will increase the trade group's considerable coffers to more than $300 million per year," according to Politico, "a financial advantage it hasn't enjoyed since 2009, when drug makers came out largely unscathed in Obamacare negotiations."
Politico first reported on PhRMA's board voting to raise dues in August, but didn't know then by how much. "They are formidable under any scenario. They are formidable now," Hillary Clinton health policy adviser Chris Jennings said at the time. "The idea that they are going to bring in more resources, borders on petrifying."
But an angry public, led by progressive voices, is potentially just as formidable.
A recent poll found that more than three in four Americans believe that prescription drug prices are "unreasonable," with large majorities from both major political parties in favor of government steps to keep those prices down.
On Monday, STAT reported that "a coalition of 300 institutional investors has filed shareholder resolutions with 11 big U.S. drug makers to explain and justify all price increases and the risks these may pose to stockholders."
And just last week, Sen. Bernie Sanders (I-Vt.) penned an op-ed in favor of the California Drug Price Relief Act, also known as Proposition 61, which seeks to rein in prescription drug prices. Voting yes on Proposition 61, he wrote on Friday, would not only help "make medicine more affordable in California," but would also "send a signal to Washington that the whole nation's prescription drug policies need an overhaul."
Big Pharma has been ardently fighting that measure, as Politico reports--though polls suggest the ballot measure is still poised to win.
On Tuesday, Sanders tweeted in response to the Politico piece:
And he pushed back on the narrative that Big Pharma is likely to employ in its effort to clean up its image.
As the group Health GAP, which campaigns for HIV drug access worldwide, wrote Tuesday on Twitter: "PhRMA is filling a war chest & preparing for battle to keep drug prices high. We need to be prepared to fight back!"
Deirdre Fulton
Deirdre Fulton is a former Common Dreams senior editor and staff writer. Previously she worked as an editor and writer for the Portland Phoenix and the Boston Phoenix, where she was honored by the New England Press Association and the Association of Alternative Newsweeklies. A Boston University graduate, Deirdre is a co-founder of the Maine-based Lorem Ipsum Theater Collective and the PortFringe theater festival. She writes young adult fiction in her spare time.
Facing an increasingly outraged public, the leading Big Pharma lobby group is hiking its annual dues by more than 50 percent as it prepares to defend its pharmaceutical company members against lawmakers and voters who want to rein in out-of-control drug prices.
Politico reported Tuesday that "PhRMA hopes to improve its public image next year and stave off any legislative action" in the wake of recent public scandals like those over EpiPen and Valeant. "It plans to run TV ads emphasizing how new drugs could add years to patients' lives, as well as the years of complex research needed to develop a drug--in other words, a lot of money that must be recouped through high prices."
To do so, it needs some extra cash.
As such, "PhRMA's decision to hike membership dues 50 percent will increase the trade group's considerable coffers to more than $300 million per year," according to Politico, "a financial advantage it hasn't enjoyed since 2009, when drug makers came out largely unscathed in Obamacare negotiations."
Politico first reported on PhRMA's board voting to raise dues in August, but didn't know then by how much. "They are formidable under any scenario. They are formidable now," Hillary Clinton health policy adviser Chris Jennings said at the time. "The idea that they are going to bring in more resources, borders on petrifying."
But an angry public, led by progressive voices, is potentially just as formidable.
A recent poll found that more than three in four Americans believe that prescription drug prices are "unreasonable," with large majorities from both major political parties in favor of government steps to keep those prices down.
On Monday, STAT reported that "a coalition of 300 institutional investors has filed shareholder resolutions with 11 big U.S. drug makers to explain and justify all price increases and the risks these may pose to stockholders."
And just last week, Sen. Bernie Sanders (I-Vt.) penned an op-ed in favor of the California Drug Price Relief Act, also known as Proposition 61, which seeks to rein in prescription drug prices. Voting yes on Proposition 61, he wrote on Friday, would not only help "make medicine more affordable in California," but would also "send a signal to Washington that the whole nation's prescription drug policies need an overhaul."
Big Pharma has been ardently fighting that measure, as Politico reports--though polls suggest the ballot measure is still poised to win.
On Tuesday, Sanders tweeted in response to the Politico piece:
And he pushed back on the narrative that Big Pharma is likely to employ in its effort to clean up its image.
As the group Health GAP, which campaigns for HIV drug access worldwide, wrote Tuesday on Twitter: "PhRMA is filling a war chest & preparing for battle to keep drug prices high. We need to be prepared to fight back!"
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.